Loading...
•
Sep 27, 2025
USANA Q3 2025 Earnings Report
USANA Health Sciences reported its third quarter 2025 financial results, including a net sales increase and a net loss.
Key Takeaways
USANA Health Sciences reported a 7% year-over-year increase in net sales, reaching $214 million for Q3 2025. However, the company experienced a net loss of $6.5 million, or -$0.36 diluted EPS, primarily due to softer than anticipated sales, investments in a new Brand Partner compensation plan, and a significant adjustment to the estimated annual effective income tax rate.
Net sales increased by 7% year-over-year to $214 million, driven by the acquisition of Hiya and growth in the Americas and Europe region.
The company reported a net loss of $6.5 million and diluted EPS of -$0.36, a significant decline from a net income of $10.6 million and $0.56 EPS in the prior year.
Adjusted diluted EPS was -$0.15, compared to $0.56 in the prior year, reflecting the impact of acquisition-related costs and tax adjustments.
Active Customers in the direct selling business decreased to 388,000 from 452,000 in the prior year, while Hiya reported 193,400 active monthly subscribers.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
USANA updated its fiscal year 2025 outlook, lowering expectations for consolidated net sales, net earnings, and diluted EPS, reflecting challenges from Q3 performance and anticipated one-time charges.
Positive Outlook
- Hiya is expected to generate double-digit sales growth for 2025, with an updated forecast of approximately $132 million in net sales, reflecting 16% year-over-year growth.
- The company is executing a comprehensive process to align costs globally with current sales levels, which is expected to improve future profitability.
- Management is encouraged by the pickup in sales activity and leader productivity in recent weeks following the rollout of the enhanced Brand Partner compensation plan.
- The enhanced compensation plan and new product launches are strategic moves to modernize the business and position for long-term success.
- Fiscal year 2025 is a 53-week year, including one additional week of sales compared to fiscal 2024, which will contribute to overall sales.
Challenges Ahead
- Consolidated net sales outlook for fiscal year 2025 was updated to $920 million, down from a previous range of $920 million to $1.0 billion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...